Bristol-Myers updates results from studies evaluating Opdivo
Bristol-Myers Squibb announced updated results from studies evaluating Opdivo alone or in combination, in patients with advanced or metastatic melanoma. These analyses will be featured on Monday, June 3 from 1:15-4:15 PM CDT at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago. A five-year analysis of the Phase 1 CA209-004 study, the longest follow-up for the Opdivo plus Yervoy combination in patients with previously treated or untreated advanced melanoma to date, showed that with a median follow-up of 43.1 months in all patients, at four years or longer, overall survival rates were stable at 57%.The three-year OS rate following discontinuation of therapy was 56%. The study also showed long-term survival outcomes with Opdivo plus Yervoy, regardless of BRAF or lactate dehydrogenase status, with four-year OS rates of 62% versus 49% for patients with normal and elevated LDH, respectively, and four-year OS rates of 54% and 61% for patients with wild-type and mutant BRAF tumors, respectively. The overall safety of the combination was consistent with previously reported studies of these medicines in patients with advanced melanoma.